Harbor Health Care ETF (MEDI)
- Previous Close
25.40 - Open
25.29 - Bid 12.62 x 1000
- Ask 37.86 x 1000
- Day's Range
25.27 - 25.27 - 52 Week Range
20.73 - 27.48 - Volume
627 - Avg. Volume
7,022 - Net Assets 10.18M
- NAV 25.35
- PE Ratio (TTM) 38.55
- Yield 0.60%
- YTD Daily Total Return 2.19%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.80%
The fund invests primarily in equity securities, principally common and preferred stocks of companies of any market capitalization. Under normal market conditions, the fund invests at least 80% of its net assets, plus borrowings for investment purposes, in securities of companies principally engaged in the research, development, production, or distribution of products and services related to the health care industry (“health care companies”). It is non-diversified.
Harbor
Fund Family
Health
Fund Category
10.18M
Net Assets
2022-11-16
Inception Date
Performance Overview: MEDI
Trailing returns as of 4/18/2024. Category is Health.
People Also Watch
Holdings: MEDI
Top 10 Holdings (63.22% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: MEDI
LGND: Lowering target price to $84.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice TargetMYGN: Lowering target price to $20.00
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetMYGN: Raising target price to $22.00
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetLGND: Raising target price to $86.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice Target